{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:52:54Z","timestamp":1777593174039,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.exphem.2013.01.005","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T03:18:44Z","timestamp":1358565524000},"page":"491-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings"],"prefix":"10.1016","volume":"41","author":[{"given":"Violeta","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivonne","family":"Archibeque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josie","family":"Han Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bee-Chun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie B.","family":"Schenkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Geuns-Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Emkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2013.01.005_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2013.01.005_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nchembio.297","article-title":"The (un)targeted cancer kinome","volume":"6","author":"Fedorov","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.exphem.2013.01.005_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/bj3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors","volume":"351","author":"Davies","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2013.01.005_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2013.01.005_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.exphem.2013.01.005_bib6","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2013.01.005_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2013.01.005_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd2541","article-title":"High-throughput kinase profiling as a platform for drug discovery","volume":"7","author":"Goldstien","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2013.01.005_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17460441.3.6.607","article-title":"The challenge of selecting protein kinase assays for lead discovery optimization","volume":"3","author":"Ma","year":"2008","journal-title":"Expert Opin Drug Dis"},{"key":"10.1016\/j.exphem.2013.01.005_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1087057108326663","article-title":"High-throughput biochemical kinase selectivity assays: Panel development and screening","volume":"14","author":"Card","year":"2009","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.exphem.2013.01.005_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2013.01.005_bib12","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.01.005_bib13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/asheducation-2009.1.636","article-title":"Therapeutic potential of JAK2 inhibitors","author":"Verstovsek","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2013.01.005_bib14","series-title":"Annual reports in medicinal chemistry volume 44","first-page":"247","article-title":"Advances in the discovery of small molecule JAK3 inhibitors","author":"Wrobleski","year":"2009"},{"key":"10.1016\/j.exphem.2013.01.005_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2013.01.005_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2013.01.005_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2013.01.005_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2013.01.005_bib19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.270.5237.794","article-title":"Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3","volume":"270","author":"Thomis","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.exphem.2013.01.005_bib20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.exphem.2013.01.005_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2013.01.005_bib22","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1172\/JCI200422315","article-title":"TYK2 is a key regulator of the surveillance of B lymphoid tumors","volume":"114","author":"Stoiber","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2013.01.005_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","article-title":"The JAK kinases: not just another kinase drug discovery target","volume":"19","author":"Wilks","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.exphem.2013.01.005_bib24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: in\u00a0vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.01.005_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","article-title":"Ba\/F3 cells and their use in kinase drug discovery","volume":"19","author":"Warmuth","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.exphem.2013.01.005_bib26","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood.V95.6.2076","article-title":"Transforming properties of chimeric TEL-JAK proteins in Ba\/F3 cells","volume":"95","author":"Lacronique","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.01.005_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmpb.2006.01.008","article-title":"Robust regression for high throughput drug screening","volume":"82","author":"Fomenko","year":"2006","journal-title":"Comput Meth Prog Bio"},{"key":"10.1016\/j.exphem.2013.01.005_bib28","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune disease and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.exphem.2013.01.005_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1874940200801010080","article-title":"Kinetic study of human full-length wild-type JAK2 and V617F mutant proteins","volume":"1","author":"Erdman","year":"2008","journal-title":"Open Enzyme Inhibition J"},{"key":"10.1016\/j.exphem.2013.01.005_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","article-title":"Features of selective kinase inhibitors","volume":"12","author":"Knight","year":"2005","journal-title":"Chem Biol"},{"key":"10.1016\/j.exphem.2013.01.005_bib31","doi-asserted-by":"crossref","first-page":"8440","DOI":"10.1021\/jm200911r","article-title":"Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors","volume":"54","author":"Schenkel","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.exphem.2013.01.005_bib32","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X13000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X13000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:56Z","timestamp":1759566656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X13000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0301472X13000064"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2013.01.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2013.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}